🇺🇸 FDA
Patent

US 9765338

Modulation of dystrophia myotonica-protein kinase (DMPK) expression

granted A61PA61P15/00A61P21/00

Quick answer

US patent 9765338 (Modulation of dystrophia myotonica-protein kinase (DMPK) expression) held by Ionis Pharmaceuticals, Inc. expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P15/00, A61P21/00, A61P21/04, A61P25/14